Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma

Renal cell carcinoma (RCC) frequently recurs or metastasizes after surgical resection. Everolimus, an mTOR inhibitor, is used as a second-line treatment, but the response of RCC to everolimus is insufficient. Metformin is an antidiabetic drug; recent reports have indicated its anti-cancer effects in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Seong-Hwi, Lee, Kwang-Suk, Hwang, Hyun-Ji, Park, Sung-Yul, Han, Woong-Kyu, Yoon, Young-Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319793/
https://www.ncbi.nlm.nih.gov/pubmed/35885994
http://dx.doi.org/10.3390/genes13071211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319793/
https://www.ncbi.nlm.nih.gov/pubmed/35885994
http://dx.doi.org/10.3390/genes13071211

Ejemplares similares